The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, hyperphagia in Prader-Willi syndrome, endometriosis and uterine fibroids , as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. Strong working knowledge of technology risk domains, including cybersecurity, cloud, identity and access management, IT general controls, automated application controls, systems development and implementation, technology resiliency and disaster recovery, data governance and privacy, third-party risk, AI governance, and enterprise systems.